Horizon Therapeutics PLC (NASDAQ:HZNP)
| 91.47 Delayed Data As of Apr 09 |  +0.47 / +0.52%Today’s Change | 30.00 Today|||52-Week Range 96.54 | +25.04% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $20.5B |
Company Description
Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.
Contact Information
Horizon Therapeutics Plc Connaught House Dublin Dublin 4 |
Employees
Shareholders
| Mutual fund holders | 47.46% |
| Other institutional | 43.29% |
| Individual stakeholders | 1.22% |
Top Executives
| Timothy P. Walbert | Chairman, President & Chief Executive Officer |
| Paul W. Hoelscher | Chief Financial Officer & Executive Vice President |
| Jeffrey W. Sherman | Chief Medical Officer & Executive Vice President |
| Jeffrey D. Kent | Executive VP-Medical Affairs & Outcomes Research |
| Karin Rosen | Chief Scientific Officer |
